PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Bharat Biotech International, Hyderabad, India.\', \'WB Statistical Consulting, Bethesda, MA, USA.\', \'National Institute of Virology, Indian Council of Medical Research, Pune, India.\', \'National Institute of Cholera and Enteric Diseases, Indian Council of Medical Research, Kolkatta, India.\', \'All India Institute of Medical Sciences, New Delhi, India.\', \'Nizams Institute of Medical Sciences, Hyderabad, India.\', \'Pandit Bhagwat Dayal Sharma Post Graduate Institute of Medical Sciences, Rohtak, India.\', \'All India Institute of Medical Sciences, Patna, India.\', \'Redkar Hospital, Panjim, India.\', \'SRM Hospital and Research Centre, Chennai, India.\', \'ESIC Medical College and Hospital, Faridabad, India.\', \'Mahatma Gandhi Medical College and Research Institute, Pondicherry, India.\', \'Department of Community Medicine, People\'s College of Medical Sciences and Research Centre, People\'s University, Bhopal, India.\', \'Rahate Surgical Hospital, Nagpur, India.\', \'Aligarh Muslim University, Aligarh, India.\', \'GMERS Medical College and Civil Hospital, Ahmedabad, India.\', \'Government Fever Hospital, Guntur, India.\', \'Indian Council of Medical Research, New Delhi, India.\', \'Bharat Biotech International, Hyderabad, India. Electronic address: kmohan@bharatbiotech.com.\']
?:citedBy
  • -1
?:creator
?:doi
  • S0140-6736(21)02000-610.1016/S0140-6736(21)02000-6
?:doi
?:hasPublicationType
?:journal
  • Lancet (London, England)
is ?:pmid of
?:pmid
?:pmid
  • 34774196
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • -1.0
?:rankingScore_hIndex
  • -1
is ?:relation_isRelatedTo_publication of
?:title
  • Efficacy, safety, and lot-to-lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): interim results of a randomised, double-blind, controlled, phase 3 trial.
?:type
?:year
  • 2021

Metadata

Anon_0  
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/net/provenance/ns#DataItem>
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://www.w3.org/2004/03/trix/rdfg-1/Graph>
<http://xmlns.com/foaf/0.1/primaryTopic> <https://research.tib.eu/covid-19/entity/34774196>
<http://xmlns.com/foaf/0.1/topic> Anon_0
<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes> <https://research.tib.eu/covid-19/data/entity/34774196>
<http://purl.org/net/provenance/ns#createdBy>
Anon_1   (more)
expand all